Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114140 · ClinicalTrials.gov registry record · Phase 2
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00114140 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 136 participants.
The verdict
NCT00114140, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temozolomide together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving temozolomide together with radiation therapy works in treating patients with low-grade gliomas.
Interventions
- DRUG Temozolomide
- RADIATION Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2005-01 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114140
The ClinicalTrials.gov registry entry for NCT00114140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00114140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114140 about?
NCT00114140 is a clinical study titled "Temozolomide and Radiation Therapy in Treating Patients With Gliomas". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temozolomide together with radiation therapy may...
What is the current status of trial NCT00114140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2005-01. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00114140?
The interventions under investigation include: Temozolomide (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00114140?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.